PMC7390822_01
Durable clinical response to Nivolumab in a non-small cell lung cancer (NSCLC) patient with epidermal growth factor receptor (EGFR) driver mutations. (A) Clinical timeline of patient, with major treatment indicated. The patient has been benefitting from immunotherapy for more than 19 months. (B) Chest computed tomography (CT) of the metastatic lung tumors before Nivolumab initiation (June 2018) and last time follow-up (January 2020). (C) Magnetic resonance imaging (MRI) before and after Nivolumab treatment. Images in the middle revealed an increased size of the left basal ganglia lesion accompanied by edema and multiple brain nodule metastases. A rapid decrease in lesions was noted in the following radiological evaluations.
fimmu-11-01366-g0001.jpg
PMC7390822_01_fimmu-11-01366-g0001.jpg
F1
T4N2M1b stage IV (Figure 1A). The patient was initially treated with Icotinib from February 2017 until progression occurred in July 2017. After systemic chemotherapy, he turned to traditional Chinese medicine treatment, until the onset of brain metastases in the right frontal lobe and left basal ganglia in June 2018 (Figures 1B,C). August 2018, and magnetic resonance imaging (MRI) scans showed an increased lesion size and edema of the left basal ganglia, as well as multiple brain metastases (Figure 1C).